Information Provided By: 
Fly News Breaks for September 5, 2017
INSM
Sep 5, 2017 | 13:32 EDT
Cowen analyst Ritu Baral noted that Insmed reported "strong" efficacy and safety data for ALIS, which she thinks will drive approval of the drug in the U.S., EU and Japan. Given the increased probability of success, she set a $54 price target on Insmed shares, which have more than doubled to $26.37 in early afternoon trading.
News For INSM From the Last 2 Days
There are no results for your query INSM
